Changeflow GovPing Pharma & Healthcare Comparative Efficacy of Topical Clotrimazole Ve...
Routine Notice Added Final

Comparative Efficacy of Topical Clotrimazole Versus 2% Salicylic Acid in Otomycosis

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH has registered a randomized controlled clinical trial (NCT07535424) comparing clotrimazole ear drops versus 2% salicylic acid ear drops for treatment of otomycosis (fungal ear canal infection). The study enrolled 60 patients randomized equally between the two treatment groups, with both interventions administered three times daily for two weeks. The primary outcome measure is relief of ear blockage reflecting improvement in canal patency.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new clinical trial (NCT07535424) on ClinicalTrials.gov comparing clotrimazole ear drops to 2% salicylic acid ear drops for treating otomycosis. The randomized controlled study enrolled 60 patients diagnosed with otomycosis, with equal allocation to each treatment arm. Both groups received their assigned intervention three times daily for two weeks, with assessment at baseline and endpoint. The primary outcome measure is relief of ear blockage reflecting improvement in canal patency.

For healthcare providers and clinical investigators, this trial registration provides evidence of an ongoing comparative effectiveness study for a common fungal ear condition. The results may inform future treatment guidelines for selecting between these two topical antifungal options based on clinical efficacy data.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Comparative Efficacy of Topical Clotrimazole Versus 2% Salicylic Acid in Otomycosis

N/A NCT07535424 Kind: NA Apr 17, 2026

Abstract

Otomycosis is a fungal infection of the outer ear canal that commonly causes itching, discomfort, discharge, and a feeling of blockage in the ear. This randomized controlled study was conducted to compare two commonly used topical treatments for otomycosis: clotrimazole ear drops and 2% salicylic acid ear drops. A total of 60 patients diagnosed with otomycosis were enrolled and were randomly assigned in equal numbers to one of the two treatment groups. One group received clotrimazole drops three times daily for two weeks, while the other group received 2% salicylic acid drops at the same frequency and for the same duration. Patients were assessed at the start of treatment and again after two weeks. The main outcome measure was relief of ear blockage, which reflected improvement in canal patency after treatment. It was hypothesized that topical clotrimazole would be more effective than 2% salicylic acid in clearing ear blockage and improving short-term clinical recovery in patients with otomycosis. This study was conducted to provide evidence for selecting an effective, practical, and affordable topical treatment for routine clinical use.

Conditions: Otomycosis

Interventions: clotrimazole, 2% Salicylic Acid

View original document →

Named provisions

Otomycosis Clotrimazole 2% Salicylic Acid

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07535424

Who this affects

Applies to
Healthcare providers Patients Clinical investigators
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trials research Drug comparison study Pharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!